Ventripoint Diagnostics Partners to Expand Cardiac Screening and Research in Costa Rica

Toronto, Ontario — April 1, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) has partnered with the Health Division of the Montecristo Group to explore new clinical pathways for implementing Ventripoint’s VMS+™ cardiac imaging platform in Costa Rica.

The collaboration aims to expand access to advanced cardiac diagnostics, including remote screening for congenital and structural heart disease. It will also integrate VMS+™ technology into clinical research and clinical trial programs, and broaden the deployment of VMS+™ AI-assisted echocardiography solutions for patients across Costa Rica.

These initiatives are intended to improve accuracy in heart monitoring and increase access to modern diagnostic tools for both public and private healthcare systems.

The organizations will explore how the VMS+™ system can support hospitals, physicians, and research organizations by enhancing the accuracy of cardiac imaging and enabling earlier detection of heart conditions, especially in underserved or remote communities.

Hugh MacNaught, President & CEO of Ventripoint Diagnostics, stated that the company is excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica. He cited their strong healthcare network, commitment to affordable high-quality care, and passion for innovation as reasons that make them an ideal partner for expanding access to advanced cardiac diagnostics and supporting clinical research opportunities in central America.

Catalina Ulloa, Director of the Metropolitano Research Institute, Hospital Metropolitano, Grupo Montecristo, noted the institute is proud to serve as the research partner of Ventripoint Diagnostics in Costa Rica. Ulloa added that the partnership enables them to translate advanced AI-driven cardiac imaging into real-world impact by expanding early detection, improving diagnostic accuracy, and increasing access to high-quality cardiovascular care.

The collaboration is expected to support research partnerships, technology deployment initiatives, and clinical trial (CRO) programs that incorporate VMS+ as an affordable advanced cardiac measurement tool that supports new care models and pathways.

The Health Division of the Montecristo Group, part of a leading corporate group in Costa Rica, focuses on advancing healthcare access, innovation, and patient-centered medical services. Through a network of healthcare companies and medical facilities, including Hospital Metropolitano, the division aims to provide high-quality medical care, promote preventative health, and introduce innovative healthcare solutions that improve wellbeing for communities across Costa Rica and the region.

Ventripoint Diagnostics Ltd. applies AI to echocardiography. Ventripoint's VMS products are powered by its Knowledge Based Reconstruction technology, which provides volumetric cardiac measurements equivalent to MRI. VMS+ can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Source: Ventripoint Diagnostics Ltd.